Boston Scientific Corporation (BSX) traded within a range of $25.13 to $25.52 after opening the day at $25.43. The company has seen its stock increase in value by 17.24% so far this year. The stock was down close to -0.2% on light volume in last trading session and closed at $25.36 per share. After the recent fall, the stock is currently holding -1.13% below its 52 week high of $25.65 and 52.59% above its 12-month low of $16.82. The shares are up by over 19.96% in the last three months, and the RSI indicator value of 74.38 is bearish. The technical indicator is offering a warning sign that the stock can’t keep current pace going.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; coronary technology products to treat atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems. It also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters used to treat peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat, diagnose, and ease benign and malignant tumors. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable cardiac resynchronization therapy pacemaker systems used to treat heart failure; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising steerable radio frequency ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories. Further, it provides products to diagnose and treat diseases of the pulmonary and gastrointestinal conditions; devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs; products to treat urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products, sling and graft materials, pelvic floor reconstruction kits, and suturing devices; and spinal cord stimulator systems. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Delta Air Lines, Inc. (DAL) failed to extend gains with the stock declining -0.66% or $-0.34 to close the day at $50.83 on light trading volume of 6.61M shares, compared to its three month average trading volume of 7.63M. The Atlanta Georgia 30354 based company has been outperforming the major airlines group over the past 52 weeks, with the stock gaining 10.87%, compared to the industry which has advanced 18.31% over the same period. With RSI of 58.85, the stock should still continue to rise and get closer to its one year target estimate of $0, making it a hold for now.
Delta Air Lines, Inc. provides scheduled air transportation for passengers and cargo in the United States and internationally. The company operates through two segments, Airline and Refinery. Its route network is centered around a system of hubs, international gateways, and airports in Amsterdam, Atlanta, Boston, Detroit, London-Heathrow, Los Angeles, Minneapolis-St. Paul, New York-LaGuardia, New York-JFK, Paris-Charles de Gaulle, Salt Lake City, Seattle, and Tokyo-Narita. The company sells its tickets through various distribution channels, including delta.com and mobile applications/Web, telephone reservations, online travel agencies, traditional brick and mortar, and other agencies. It also provides aircraft maintenance, repair, and overhaul services; staffing, and professional security and training services, as well as aviation solutions to third parties; vacation packages to third-party consumers; and aircraft charters, and aircraft management and programs. As of February 2, 2017, the company operated a fleet of approximately 800 aircraft. Delta Air Lines, Inc. was founded in 1924 and is headquartered in Atlanta, Georgia.
Reynolds American Inc. (RAI) gained $0.28 to close the day at a new closing price of $60.71, a 0.46% increase in value from its previous closing price that moved the stock 41.12% above its 52 week low of $43.38. A total of 6.55M shares exchanged hands during the day compared with its three month average trading volume of 7.46M. The stock, which fluctuated between $60.27 and $60.83 during the day, currently situated -0.33% below its 52 week high. The stock is up by 4.67% in the past one month and up by 14.06% over the past three months. With a one year target estimate of $57.01 and RSI of 71.62, the stock still has upside potential, making it a sell for now.
Reynolds American Inc., through its subsidiaries, manufactures, and sells cigarettes and other tobacco products in the United States. It operates through RJR Tobacco, Santa Fe, and American Snuff segments. The RJR Tobacco segment offers cigarettes under the NEWPORT, CAMEL, PALL MALL, DORAL, MISTY, and CAPRI brands; and CAMEL Snus, a smoke-free tobacco product, as well as manages various licensed brands, including DUNHILL and STATE EXPRESS 555. The Santa Fe segment manufactures and markets cigarettes and other tobacco products under the NATURAL AMERICAN SPIRIT brand. The American Snuff segment provides smokeless tobacco products, such as moist snuff under GRIZZLY and KODIAK brand names. The company also manufactures and markets digital vapor cigarettes under the VUSE brand name; and markets nicotine replacement therapy products under the ZONNIC brand. It distributes its products primarily through direct wholesale deliveries from a local distribution center and public warehouses. Reynolds American Inc. was founded in 2004 and is headquartered in Winston-Salem, North Carolina.